Cases & Deals

  • Home
  • Practices
  • Celgene appeals decision from Opposition Division to revoke lenalidimide European patent

Share

Celgene appeals decision from Opposition Division to revoke lenalidimide European patent

November 2014

Client(s) Celgene Corporation

Jones Day represents Celgene Corporation in the appeal of a decision in opposition proceedings against two generic companies opposing a Celgene European patent covering the polymorphs of lenalidimide.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.